Pricing Log in Create free account
Friday 6 November 2026 Export EW’s income statement to Excel — free account

Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue
+10.5%
EPS
+4.60%
Free cash flow
−1.84%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

101.94 1.12 +1.11%
Market cap
$58.1B
P/E
57.8×
Fwd P/E
36.5×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Edwards Lifesciences Corporation 10-Q filed May 6, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 4:12 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 6 added · 7 removed · 33 modified; 5 with only figures updated; 1 moved without change

  1. Modified · Overview

    We are the leading global structural heart disease innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We conduct operations worldwide and are managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Our products are categorized into the following groups: Transcatheter Aortic Valve Replacement (“TAVR”), Transcatheter Mitral and Tricuspid Therapies (“TMTT”), and Surgical Structural Heart (“Surgical”).